These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 27906698)

  • 41. Dupilumab utility in difficult-to-treat asthma.
    M Walsh G
    Immunotherapy; 2019 Mar; 11(4):261-264. PubMed ID: 30678554
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies.
    Wright LS; Phipatanakul W
    Ann Allergy Asthma Immunol; 2016 Jul; 117(1):17-20. PubMed ID: 27371967
    [No Abstract]   [Full Text] [Related]  

  • 45. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
    Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
    Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benralizumab as a potential treatment of asthma.
    Antoniu SA
    Expert Opin Biol Ther; 2017 Jul; 17(7):895-900. PubMed ID: 28406319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New and Anticipated Therapies for Severe Asthma.
    Peters SP; Busse WW
    J Allergy Clin Immunol Pract; 2017; 5(5S):S15-S24. PubMed ID: 28888244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologic agents for severe asthma patients: clinical perspectives and implications.
    Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
    Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS; Kariyawasam HH
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
    Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
    Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omalizumab: efficacy in allergic disease.
    Spector S
    Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
    Matucci A; Maggi E; Vultaggio A
    Respir Med; 2019; 160():105819. PubMed ID: 31734469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic interventions in severe asthma.
    Canonica GW; Senna G; Mitchell PD; O'Byrne PM; Passalacqua G; Varricchi G
    World Allergy Organ J; 2016; 9(1):40. PubMed ID: 27942351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.